The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Zyryanov S.K.

Peoples’ Friendship University of Russia (RUDN University)

Butranova O.I.

Peoples’ Friendship University of Russia

Putsman G.A.

Peoples’ Friendship University of Russia;
City Clinical Hospital No. 24

The efficacy of the combination of diclofenac and orphenadrine in the treatment of dorsalgia

Authors:

Zyryanov S.K., Butranova O.I., Putsman G.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(5): 126‑133

DOI: 10.17116/jnevro2021121051126

Read: 4180 times

Download PDF (RU)
Contact the author
Table of contents

THE EFFICACY OF THE COMBINATION OF DICLOFENAC AND ORPHENADRINE IN THE TREATMENT OF DORSALGIA
THE EFFICACY OF THE COMBINATION OF DICLOFENAC AND ORPHENADRINE IN THE TREATMENT OF DORSALGIA

To cite this article:

Zyryanov SK, Butranova OI, Putsman GA. The efficacy of the combination of diclofenac and orphenadrine in the treatment of dorsalgia. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(5):126‑133. (In Russ.)
https://doi.org/10.17116/jnevro2021121051126

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
On the resu­lts of a multicenter, open, obse­rvational, non-interventional study of the effi­cacy and safety of nime­sulide (Nise) in combination with muscle rela­xants in patients with acute back pain. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):82-88
Risk factors for low back pain in healthcare professionals taking care for patients with redu­ced mobi­lity. Russian Journal of Preventive Medi­cine. 2025;(7):75-80
Comparative analysis of the effe­ctiveness of outpatient reha­bilitation algo­rithms for patients with back pain. Problems of Balneology, Physiotherapy and Exercise Therapy. 2025;(5-2):72-80
SPA reha­bilitation of patients with lumbar spine dorsopathy. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2025;(4):14-19
Abstract:

The high prevalence of dorsalgia and dorsopathy among the adult population makes a significant contribution to the structure of the financial burden of health care systems. The use of non-steroidal anti-inflammatory drugs (NSAIDs) as the basis for the pharmacotherapy of dorsopathy is recommended by most international clinical guidelines. The pharmacodynamic effects of NSAIDs underlie the clinical efficacy of this group of drugs in patients with pain of musculoskeletal origin, while monotherapy is not always accompanied by the rapid development of a persistent analgesic effect. An urgent direction in the therapy of dorsopathies may include combination of NSAIDs with analgesic drugs of other pharmacological groups capable of additive action. The fixed combination of diclofenac, 75 mg, and orphenadrine, 50 mg, allows achieving an effective analgesic effect in patients with lower back pain of various etiologies. It was demonstrated in a series of clinical cases that included 4 patients with dorsopathy who were treated at the City Clinical Hospital No. 24, Moscow in 2020.

Keywords:

dorsopathy
low back pain
non-steroidal anti-inflammatory drugs (NSAIDs)
diclofenac
orphenadrine

Authors:

Zyryanov S.K.

Peoples’ Friendship University of Russia (RUDN University)

Butranova O.I.

Peoples’ Friendship University of Russia

Putsman G.A.

Peoples’ Friendship University of Russia;
City Clinical Hospital No. 24

Received:

11.03.2021

Accepted:

19.04.2021

Close metadata

References:

  1. Carregaro RL, Tottoli CR, Rodrigues DDS, Bosmans JE, da Silva EN, van Tulder M. Low back pain should be considered a health and research priority in Brazil: Lost productivity and healthcare costs between 2012 to 2016. PLoS One. 2020;15(4):e0230902. Published 2020 Apr 1.  https://doi.org/10.1371/journal.pone.0230902
  2. Kim LH, Vail D, Azad TD, Bentley JP, Zhang Y, Ho A.L., Fatemi P, Feng A, Varshneya K, Desai M, Veeravagu A, Ratliff JK. Expenditures and Health Care Utilization Among Adults With Newly Diagnosed Low Back and Lower Extremity Pain. JAMA Netw Open. 2019;2(5):e193676. https://doi.org/10.1001/jamanetworkopen.2019.3676
  3. Meucci RD, Fassa AG, Faria NM. Prevalence of chronic low back pain: systematic review. Rev Saude Publica. 2015;49:1.  https://doi.org/10.1590/S0034-8910.2015049005874
  4. Fatoye F, Gebrye T, Odeyemi I. Real-world incidence and prevalence of low back pain using routinely collected data. Rheumatol Int. 2019;39:619-626.  https://doi.org/10.1007/s00296-019-04273-0
  5. Wu A, March L, Zheng X, Huang J, Wang X, Zhao J, Blyth FM, Smith E, Buchbinder R, Hoy D. Global low back pain prevalence and years lived with disability from 1990 to 2017: estimates from the Global Burden of Disease Study 2017. Ann Transl Med. 2020;8(6):299.  https://doi.org/10.21037/atm.2020.02.175
  6. Oliveira CB, Maher CG, Pinto RZ, Traeger AC, Lin CC, Chenot JF, van Tulder M, Koes BW. Clinical practice guidelines for the management of non-specific low back pain in primary care: an updated overview. Eur Spine J. 2018;27(11):2791-2803. https://doi.org/10.1007/s00586-018-5673-2
  7. van der Gaag WH, Roelofs PDDM, Enthoven WTM, van Tulder MW, Koes BW. Non‐steroidal anti‐inflammatory drugs for acute low back pain. Cochrane Database of Systematic Reviews. 2020;4:Art. No.: CD013581. Accessed 27 February 2021. https://doi.org/10.1002/14651858.CD013581
  8. Noninvasive Treatments for Low Back Pain [Internet]. Comparative Effectiveness Reviews, No. 169. Chou R, Deyo R, Friedly J, Skelly A, Hashimoto R, Weimer M, Fu R, Dana T, Kraegel P, Griffin J, Grusing S, Brodt E. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Feb. 
  9. McGettigan P, Henry D. Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS Med. 2013;10(2):e1001388. https://doi.org/10.1371/journal.pmed.1001388
  10. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006;116(1):4-15.  https://doi.org/10.1172/JCI27291
  11. Gan TJ. Diclofenac: an update on its mechanism of action and safety profile. Curr Med Res Opin. 2010;26(7):1715-1731. https://doi.org/10.1185/03007995.2010.486301
  12. Hinz B, Chevts J, Renner B, Wuttke H, Rau T, Schmidt A, Szelenyi I, Brune K, Werner U. Bioavailability of diclofenac potassium at low doses. Br J Clin Pharmacol. 2005;59(1):80-84.  https://doi.org/10.1111/j.1365-2125.2005.02226.x
  13. Schaffler K, Reitmeir P. Analgesic effects of low-dose intravenous orphenadrine in the state of capsaicin hyperalgesia. A randomised, placebo-controlled, double-blind cross-over study using laser somatosensory evoked potentials obtained from capsaicin-irritated skin in healthy volunteers. Arzneimittelforschung. 2004;54(10):673-679. PMID: 15553107. https://doi.org/10.1055/s-0031-1297020
  14. Pubill D, Verdaguer E, Canudas AM, Sureda FX, Escubedo E, Camarasa J, Pallàs M, Caminset A. Orphenadrine prevents 3-nitropropionic acid-induced neurotoxicity in vitro and in vivo. Br J Pharmacol. 2001;132(3):693-702.  https://doi.org/10.1038/sj.bjp.0703869
  15. Kornhuber J, Parsons CG, Hartmann S, Retz W, Kamolz S, Thome J, Riederer P. Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies. J Neural Transm Gen Sect. 1995;102(3):237-246.  https://doi.org/10.1007/BF01281158
  16. Desaphy JF, Dipalma A, De Bellis M, Costanza T, Gaudioso C, Delmas P, George AL Jr, Camerino DC. Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine. Pain. 2009;142(3):225-235.  https://doi.org/10.1016/j.pain.2009.01.010
  17. Pubill D, Canudas AM, Pallàs M, Sureda FX, Escubedo E, Camins A, Camarasa J. Assessment of the adrenergic effects of orphenadrine in rat vas deferens. J Pharm Pharmacol. 1999;51(3):307-312.  https://doi.org/10.1211/0022357991772303
  18. Lee SY, Oh HJ, Kim JW, Kim YG, Moon CJ, Lee EH. Pharmacokinetic study of orphenadrine using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci. 2006;839(1-2):118-123.  https://doi.org/10.1016/j.jchromb.2006.02.056
  19. Leuratti C, Loprete L, Rossini M, Frangione V, Rovati S, Radicioni M. Pharmacokinetics and Safety of a Diclofenac Sodium 75 mg/1 mL Solution (Akis/Dicloin) Administered as a Single Intravenous Bolus Injection in Healthy Men and Women. Eur J Drug Metab Pharmacokinet. 2019;44(5):681-689.  https://doi.org/10.1007/s13318-019-00558-8
  20. Aglas F, Fruhwald FM, Chlud K. Ergebnisse einer Anwendungsbeobachtung mit Diclofenac/Orphenadrin-Infusionen bei Patienten mit muskuloskelettalen Krankheiten und Funktionsstörungen [Results of efficacy study with diclofenac/orphenadrine infusions in patients with musculoskeletal diseases and functional disorders]. Acta Med Austriaca. 1998;25(3):86-90. German. PMID: 9816400.
  21. Uitz E, Aglas F, Wurm A, Rainer F. Diclofenac/Orphenadrin-Infusionstherapie bei Patienten mit aktivierten Arthrosen [Diclofenac/orphenadrine infusion therapy in patients with active arthrosis]. Wien Med Wochenschr. 1998;148(7):179-182. German. PMID: 9700867.
  22. Schaffler K, Reitmeir P, Gschanes A, Eggenreich U. Comparison of the analgesic effects of a fixed-dose combination of orphenadrine and diclofenac (Neodolpasse) with its single active ingredients diclofenac and orphenadrine: a placebo-controlled study using laser-induced somatosensory-evoked potentials from capsaicin-induced hyperalgesic human skin. Drugs R D. 2005;6(4):189-199.  https://doi.org/10.2165/00126839-200506040-00001
  23. Gombotz H, Lochner R, Sigl R, Blasl J, Herzer G, Trimmel H. Opiate sparing effect of fixed combination of diclophenac and orphenadrine after unilateral total hip arthroplasty: A double-blind, randomized, placebo-controlled, multi-centre clinical trial. Wien Med Wochenschr. 2010;160(19-20):526-534.  https://doi.org/10.1007/s10354-010-0829-7
  24. Borsodi M, Nagy E, Darvas K. Diclofenac/orphenadrin kombinált analgetikum a posztoperatív fájdalomcsillapításban [Diclofenac/orphenadrine as a combined analgetic in post-operative relief of pain]. Orv Hetil. 2008;149(39):1847-1852. Hungarian. https://doi.org/10.1556/OH.2008.28419
  25. Máálek J, Nedӗlová I, Lopourová M, Stefan M, Kostál R. Diklofenak 75 mg s orfenadinem 30 mg (NEODOLPASSE) versus placebo a piroxikam v pooperacní analgezii u artroskopií [Diclofenac 75mg. and 30 mg. orfenadine (Neodolpasse) versus placebo and piroxicam in postoperative analgesia after arthroscopy]. Acta Chir Orthop Traumatol Cech. 2004;71(2):80-83. 
  26. Haefeli M, Elfering A. Pain assessment. Eur Spine J. 2006;15(suppl 1):17-24.  https://doi.org/10.1007/s00586-005-1044-x
  27. Calderon-Ospina CA, Nava-Mesa MO, Arbeláez Ariza CE. Effect of Combined Diclofenac and B Vitamins (Thiamine, Pyridoxine, and Cyanocobalamin) for Low Back Pain Management: Systematic Review and Meta-analysis. Pain Med. 2020;21(4):766-781.  https://doi.org/10.1093/pm/pnz216
  28. Geller M, Mibielli MA, Nunes CP, da Fonseca AS, Goldberg SW, Oliveira L. Comparison of the action of diclofenac alone versus diclofenac plus B vitamins on mobility in patients with low back pain. J Drug Assess. 2016;5(1):1-3. Published 2016 Mar 31.  https://doi.org/10.3109/21556660.2016.1163263
  29. Mibielli MA, Geller M, Cohen JC, Goldberg SG, Cohen MT, Nunes CP, Oliveira LB, da Fonseca AS. Diclofenac plus B vitamins versus diclofenac monotherapy in lumbago: the DOLOR study. Curr Med Res Opin. 2009;25(11):2589-2599. https://doi.org/10.3111/13696990903246911
  30. Wijnhoven HA, de Vet HC, Picavet HS. Explaining sex differences in chronic musculoskeletal pain in a general population. Pain. 2006;124(1-2):158-166.  https://doi.org/10.1016/j.pain.2006.04.012
  31. Allegri M, Montella S, Salici F, Valente A, Marchesini M, Compagnone C, Baciarello M, Manferdini ME, Fanelli G. Mechanisms of low back pain: a guide for diagnosis and therapy [version 1; peer review: 3 approved]. F1000Research. 2016;5(F1000 Faculty Rev):1530. https://doi.org/10.12688/f1000research.8105.1
  32. Salt E, Gokun Y, Rankin Kerr A, Talbert J. A Description and Comparison of Treatments for Low Back Pain in the United States. Orthop Nurs. 2016;35(4):214-221.  https://doi.org/10.1097/NOR.0000000000000258
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.